Three-day virtual conference features over 100 internationally renowned faculty discussing latest clinical insights and data for the future of cancer care.

Physicians’ Education Resource® LLC (PER®) proudly announces that its historic 38th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow® will be held Nov. 4-6 and has transformed into an all-inclusive, three-day continuing medical education (CME)-certified, virtual, interactive experience that focuses on the state of cancer treatment today and innovative cancer breakthroughs that impact patient care strategies tomorrow.

Each year, the Chemotherapy Foundation Symposium® (CFS®) brings together more than 2,000 healthcare professionals for three days with the aim of promoting the delivery of evidence-based, state-of-the-art cancer care for both routine and the most challenging clinical scenarios. The legacy meeting will be hosted through an interactive platform that provides attendees with virtual networking opportunities throughout the robust agenda covering a broad spectrum of oncology specialties.

“The 38th Annual CFS®, is one of our largest and most influential oncology conferences of the year,” said Phil Talamo, president of PER®. “We are excited more than ever this year to provide our attendees with a VIP virtual experience and premiere access to network with the top minds in oncology. Join us in November for an impactful meeting and learn about innovative new approaches to optimize care and outcomes for patients.”

Returning co-chairs Benjamin P. Levy, M.D., and William K. Oh, M.D., are joined by Tiffany A. Traina, M.D., associate attending physician, clinical director of breast medicine service, vice chair of oncology care in the department of medicine and section head of the Triple Negative Breast Cancer Clinical Research Program at Memorial Sloan Kettering Cancer Center, to chair the conference and provide an unparalleled CME experience.

At the 38th Annual CFS® virtual conference, internationally renowned thought leaders will cover over 25 tumor types, providing participants with expert insights on the latest developments in cancer therapeutics, offering an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer. Attendees can also submit questions and participate in expert discussions real time via PER®’s custom interactive platform. To view the full agenda, click here.

Accredited by the Accreditation Council for Continuing Medical Education and the Accreditation Council for Pharmacy Education, and approved by the California Board of Registered Nursing, this live activity will provide participants with the opportunity to earn 24.25 AMA PRA Category 1 Credits™, 21.75 contact hours and 24.25 nursing contact hours.

For more information and to register, click here.

About Physicians’ Education Resource® (PER®)

Since 1995, PER® has been dedicated to advancing cancer care through professional education and now advances patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While expanding into topics outside oncology, PER® stands as the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

PER® Media Contact Alexandra Ventura, 609-716-7777 aventura@mjhlifesciences.com